4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Korro Bio, Inc. (KRRO) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 49 employees. Its market capitalization is roughly $177 million. In the fiscal year ended 2025-12-31, KRRO reported $6M in revenue and ($117M) in net income.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Interactive charts & full statements → Open the KRRO valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $6M | $2M | $0M | $0M |
| Operating Income (EBIT) | ($87M) | ($92M) | ($84M) | ($59M) |
| Net Income | ($117M) | ($84M) | ($81M) | ($58M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $1M | $1M | $2M | $2M |
| Operating Income (EBIT) | ($20M) | ($16M) | ($19M) | ($27M) | ($25M) |
| Net Income | ($20M) | ($50M) | ($18M) | ($26M) | ($23M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $114M | $226M | $222M | $74M | — |
| Total Liabilities | $62M | $66M | $52M | $173M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KRRO viewer.
About TickerBase · Data methodology & sources